Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin oral - Generex Biotechnology

Drug Profile

Insulin oral - Generex Biotechnology

Alternative Names: Insulin buccal - Generex; Oral Recosulin; Oral-lyn; Oralgen

Latest Information Update: 23 Mar 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Generex Biotechnology Corporation
  • Developer Generex Biotechnology Corporation; Leosons
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Discontinued Glucose intolerance

Most Recent Events

  • 23 Mar 2017 Discontinued - Phase-II for Glucose intolerance in Italy (Buccal) (Generex Biotechnology Corporation pipeline, March 2017)
  • 13 Jan 2017 Generex Biotechnology has patent protection for Insulin oral in USA, Canada, Monaco, Switzerland & Liechtenstein and European Union (Generex Biotechnology Corporation 10-K, January 2017)
  • 25 Aug 2015 Pharmacodynamics data from a preclinical trial in Type-II diabetes mellitus released by Generex
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top